Northway Biotech
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Nestlé and OMP Showcase Approach to Future-Ready Supply Chain at Gartner Supply Chain Symposium/Xpo in Barcelona9.5.2025 04:20:00 CEST | Press release
BARCELONA, ES / ACCESS Newswire / May 9, 2025 / OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Symposium/Xpo™ 2025 to attend Nestlé's solution provider session on May 19. The presentation will highlight how the company is transforming its supply chain across brands and regions using OMP's Unison PlanningTM. In this session, Shannon Novack, Supply Chain Excellence Expert at Nestlé, will share how the global food and beverage leader is reimagining its supply chain planning to meet increasing customer expectations in a fast-changing business environment. By leveraging advanced planning technology like Unison Planning, managing organizational change, and scalingfuture-fit capabilities, Nestlé is delivering real results. Attendees will gain valuable insights into how the company is driving adoption, overcoming transformation challenges, and aligning technology speed with organizational agility. The Gartner Supply Chain Symposium/Xpo
Innodata Reports First Quarter 2025 Results with Revenue up 120% Year-Over-Year and Reaffirms Growth Guidance of 40% or more for 20258.5.2025 16:45:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2025. Revenue of $58.3 million, representing 120% revenue growth year-over-year. Adjusted EBITDA of $12.7 million, an increase of $8.9 million from $3.8 million in the same period last year.* Net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, compared to a net income of $1.0 million, or $0.03 per basic and diluted share, in the same period last year. Cash, cash equivalents and short-term investments were $56.6 million as of March 31, 2025 and $46.9 million as of December 31, 2024. * Adjusted EBITDA is defined below. Jack Abuhoff, CEO, said, "We had a strong start to the year. We're being onboarded by potential major new customers, expanding existing relationships, and building a pipeline that's deeper and more advanced than at any point in our history. We are bringing ideas and innovation to our customers that are being w
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft8.5.2025 12:00:00 CEST | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 8, 2025 / The UK's Military Aviation Authority has issued a Military Type Certificate to the Royal Air Force's Protector RG Mk1 uncrewed aircraft, also designated the MQ-9B, certifying that it has passed a rigorous airworthiness assessment and verifying it's safe to operate without geographic restrictions, including over populous areas. This April 29 decision was a first-of-its-kind milestone for a large, unmanned aircraft system. It's a huge accomplishment for the UK and a technological watershed in the history of unmanned aircraft systems. GA-ASI is the first manufacturer of large, unmanned aircraft to receive an MTC based on rigorous compliance with STANAG 4671, the NATO standard for unmanned aircraft system airworthiness. Obtaining the MTC has been a goal of GA-ASI since the inception of the MQ-9B in January 2014. The company took its proven UAS platform, the MQ-9A, and added performance enhancing features while ensuring that the design
The Battery Show Europe 2025 Critical Agenda Highlights Moves to Global Collaboration, Regulation and Supply Chain Resilience8.5.2025 04:00:00 CEST | Press release
Featuring speakers from BMW, CATL, Mercedes Benz, Cellforce and more. STUTTGART, GERMANY / ACCESS Newswire / May 8, 2025 / The Battery Show Europe and Electric & Hybrid Vehicle Technology Expo Europe, co-located with Energy Storage Summit Germany, the region's only dedicated event for battery manufacturing, electric and hybrid vehicle tech industries, has announced its 2025 keynote lineup. The sessions will cover key themes including upcoming supply chain, navigating regulatory and policy changes and staying ahead of the curve on market trends with analysis. "Better Together: Building Resilient Battery Supply Chains Through International Collaboration," opens the program moderated by James Frith, Principal at Volta Energy Technologies, featuring insights from Isobel Sheldon, Global CEO at Western CAM Inc, Ulderico Ulissi, Head of Overseas Tech & Start-up Cooperation at CATL, Jerry Fang, Director of Business Development at Shanghai Putailai New Energy Technology Co., Ltd. and Benoit Lem
Aster Guardians Global Nursing Award Unveils Top 10 Finalists for 2025 from 100,000+ Registrations7.5.2025 10:30:00 CEST | Press release
Over 100,000 registrations received from nurses across 199* countries - a 28% increase from the third edition, which received 78,000+ registrations. One of the shortlisted Top 10 finalists will be honoured with the grand title award and a prize of USD 250,000. These finalists were selected following a rigorous evaluation process, led by esteemed expert jury and grand jury panels. The entire process is independently moderated by the appointed "Process Advisors" Ernst & Young LLP. DUBAI, AE / ACCESS Newswire / May 7, 2025 / Aster DM Healthcare has today announced the Top 10 finalists for the fourth edition of Aster Guardians Global Nursing Award - a prestigious global recognition with USD 250,000 prize money, that honours the exceptional contributions of nurses worldwide. These 10 finalists were selected from a record-breaking pool of 100,000+ registrations across 199* countries, through a stringent evaluation process led by expert jury and Grand jury panels members. The entire process i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom